Multiple anti‐atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance

Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99: 11902– 7. 7 Jang MJ, Kim NK, Chong SY, Kim HJ, Lee SJ, Kang MS, Oh D. Frequency of Pro475Ser polymorphism of ADAMTS13 gene and its association with ADAMTS-13 activity in the Korean population. Yonsei Med J 2008; 49: 405–8. 8 Gao W, Dai L, Su J, Wang Z, Ruan C. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders. Thromb Haemost 2004; 91: 1257–8. 9 Bongers TN, De Maat MP, Dippel DW, Uitterlinden AG, Leebeek FW. Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians. J Thromb Haemost 2005; 3: 805. 10 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93–100. 11 Groot E, Hulstein JJ, Rison CN, de Groot PG, Fijnheer R. FRETSVWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 698–9. 12 Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146–8. 13 Mahdian R, Rayes J, Girma JP, Houllier A, Obert B, Meyer D, Veyradier A. Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples. Thromb Haemost 2006; 95: 1049–51. 14 Miyata T, Kokame K, Banno F, Shin Y, Akiyama M. ADAMTS13 assays and ADAMTS13-deficient mice. Curr Opin Hematol 2007; 14: 277–83. 15 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097–103. 16 Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Semin Hematol 2004; 41: 68–74.

[1]  J. Eikenboom,et al.  Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[2]  M. Cattaneo.  Laboratory detection of 'aspirin resistance': what test should we use (if any)? , 2007, European heart journal.

[3]  B. Mertens,et al.  Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. , 2007, American heart journal.

[4]  F. Violi,et al.  Aspirin resistance: is this term meaningful? , 2006, Current opinion in hematology.

[5]  M. Furman,et al.  Residual Arachidonic Acid–Induced Platelet Activation via an Adenosine Diphosphate–Dependent but Cyclooxygenase-1– and Cyclooxygenase-2–Independent Pathway: A 700-Patient Study of Aspirin Resistance , 2006, Circulation.

[6]  R. Califf,et al.  Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease , 2006, Circulation.

[7]  F. Violi,et al.  Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin , 2005, Journal of thrombosis and haemostasis : JTH.

[8]  P. Gurbel,et al.  Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. , 2005, Journal of the American College of Cardiology.

[9]  A. Maree,et al.  Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. , 2005, Journal of the American College of Cardiology.

[10]  J. Eikelboom,et al.  Aspirin resistance: position paper of the Working Group on Aspirin Resistance , 2005, Journal of thrombosis and haemostasis : JTH.

[11]  M. Reeves,et al.  Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. , 2005, The American journal of cardiology.

[12]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[13]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[14]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[15]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[16]  J. Cramer.  Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. , 1998, The American journal of managed care.